Zhitong Financial APP learned that$AKESO, INC. - B (09926.HK)$Morning trading was relatively active, up about 6%. A few days ago, the company released for the first time the results of its preclinical study of the world's first TIGIT/TGF- β double-target antibody fusion protein AK130. As of press time, Kangfang Bio rose 6.07% to HK $23.60, with a turnover of HK $56 million.

A few days ago, Kangfang Biological announced that at the 2022 ESMO annual meeting, the company announced for the first time the preclinical research results of its world's first TIGIT/TGF- β double-target antibody fusion protein AK130. The results of preclinical studies fully support its clinical development in the direction of anti-tumor therapy. AK130 is the first and only new drug of TIGIT/TGF β double-target antibody fusion protein under development in the world, and it is also the first innovative drug of Kangfang biological double-target antibody fusion protein. On August 30th this year, CDE formally accepted AK130's application for clinical trials.